Selected research
Market Structure
Global Chronic Kidney Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Chronic Kidney Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Chronic Kidney Disease Drugs include AstraZeneca, F. Hoffmann-La Roche Ltd, Keryx Biopharmaceuticals, Inc, Kissei Pharmaceutical Co., Ltd, AbbVie, Amgen, GlaxoSmithKline, Pfizer and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Chronic Kidney Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Chronic Kidney Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Chronic Kidney Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Kidney Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Chronic Kidney Disease Drugs Segment by Company
AstraZeneca
F. Hoffmann-La Roche Ltd
Keryx Biopharmaceuticals, Inc
Kissei Pharmaceutical Co., Ltd
AbbVie
Amgen
GlaxoSmithKline
Pfizer
Sanofi
Teva Pharmaceutical Industries
Chronic Kidney Disease Drugs Segment by Type
Beta Blockers
Calcium Channel Blockers
Others
ACE Inhibitors
Chronic Kidney Disease Drugs Segment by Application
Hospitals
Specialty Clinics
Chronic Kidney Disease Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Kidney Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Kidney Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Kidney Disease Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Chronic Kidney Disease Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Kidney Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chronic Kidney Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Chronic Kidney Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Beta Blockers
- Calcium Channel Blockers
- Others
- ACE Inhibitors
Applications
- Hospitals
- Specialty Clinics
Companies covered
- AstraZeneca
- F. Hoffmann-La Roche Ltd
- Keryx Biopharmaceuticals, Inc
- Kissei Pharmaceutical Co., Ltd
- AbbVie
- Amgen
- GlaxoSmithKline
- Pfizer
- Sanofi
- Teva Pharmaceutical Industries
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Chronic Kidney Disease Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Chronic Kidney Disease Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Chronic Kidney Disease Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Chronic Kidney Disease Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Chronic Kidney Disease Drugs Market Dynamics
- 2.1 Chronic Kidney Disease Drugs Industry Trends
- 2.2 Chronic Kidney Disease Drugs Industry Drivers
- 2.3 Chronic Kidney Disease Drugs Industry Opportunities and Challenges
- 2.4 Chronic Kidney Disease Drugs Industry Restraints
3 Chronic Kidney Disease Drugs Market by Manufacturers
- 3.1 Global Chronic Kidney Disease Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Chronic Kidney Disease Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Chronic Kidney Disease Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Chronic Kidney Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Chronic Kidney Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Chronic Kidney Disease Drugs Manufacturers, Product Type & Application
- 3.7 Global Chronic Kidney Disease Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Chronic Kidney Disease Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Chronic Kidney Disease Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Chronic Kidney Disease Drugs Tier 1, Tier 2, and Tier 3
4 Chronic Kidney Disease Drugs Market by Type
- 4.1 Chronic Kidney Disease Drugs Type Introduction
- 4.1.1 Beta Blockers
- 4.1.2 Calcium Channel Blockers
- 4.1.3 Others
- 4.1.4 ACE Inhibitors
- 4.2 Global Chronic Kidney Disease Drugs Sales by Type
- 4.2.1 Global Chronic Kidney Disease Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Chronic Kidney Disease Drugs Sales by Type (2021-2032)
- 4.2.3 Global Chronic Kidney Disease Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Chronic Kidney Disease Drugs Revenue by Type
- 4.3.1 Global Chronic Kidney Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Chronic Kidney Disease Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Chronic Kidney Disease Drugs Revenue Market Share by Type (2021-2032)
5 Chronic Kidney Disease Drugs Market by Application
- 5.1 Chronic Kidney Disease Drugs Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Specialty Clinics
- 5.2 Global Chronic Kidney Disease Drugs Sales by Application
- 5.2.1 Global Chronic Kidney Disease Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Chronic Kidney Disease Drugs Sales by Application (2021-2032)
- 5.2.3 Global Chronic Kidney Disease Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Chronic Kidney Disease Drugs Revenue by Application
- 5.3.1 Global Chronic Kidney Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Chronic Kidney Disease Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Chronic Kidney Disease Drugs Revenue Market Share by Application (2021-2032)
6 Global Chronic Kidney Disease Drugs Sales by Region
- 6.1 Global Chronic Kidney Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Chronic Kidney Disease Drugs Sales by Region (2021-2032)
- 6.2.1 Global Chronic Kidney Disease Drugs Sales by Region (2021-2026)
- 6.2.2 Global Chronic Kidney Disease Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Chronic Kidney Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Chronic Kidney Disease Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Chronic Kidney Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Chronic Kidney Disease Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Chronic Kidney Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Chronic Kidney Disease Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Chronic Kidney Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Chronic Kidney Disease Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Chronic Kidney Disease Drugs Revenue by Region
- 7.1 Global Chronic Kidney Disease Drugs Revenue by Region
- 7.1.1 Global Chronic Kidney Disease Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Chronic Kidney Disease Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Chronic Kidney Disease Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Chronic Kidney Disease Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Chronic Kidney Disease Drugs Revenue (2021-2032)
- 7.2.2 North America Chronic Kidney Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Chronic Kidney Disease Drugs Revenue (2021-2032)
- 7.3.2 Europe Chronic Kidney Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Chronic Kidney Disease Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Chronic Kidney Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Chronic Kidney Disease Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Chronic Kidney Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 AstraZeneca
- 8.1.1 AstraZeneca Company Information
- 8.1.2 AstraZeneca Business Overview
- 8.1.3 AstraZeneca Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 AstraZeneca Chronic Kidney Disease Drugs Product Portfolio
- 8.1.5 AstraZeneca Recent Developments
- 8.2 F. Hoffmann-La Roche Ltd
- 8.2.1 F. Hoffmann-La Roche Ltd Company Information
- 8.2.2 F. Hoffmann-La Roche Ltd Business Overview
- 8.2.3 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Product Portfolio
- 8.2.5 F. Hoffmann-La Roche Ltd Recent Developments
- 8.3 Keryx Biopharmaceuticals, Inc
- 8.3.1 Keryx Biopharmaceuticals, Inc Company Information
- 8.3.2 Keryx Biopharmaceuticals, Inc Business Overview
- 8.3.3 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Product Portfolio
- 8.3.5 Keryx Biopharmaceuticals, Inc Recent Developments
- 8.4 Kissei Pharmaceutical Co., Ltd
- 8.4.1 Kissei Pharmaceutical Co., Ltd Company Information
- 8.4.2 Kissei Pharmaceutical Co., Ltd Business Overview
- 8.4.3 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Product Portfolio
- 8.4.5 Kissei Pharmaceutical Co., Ltd Recent Developments
- 8.5 AbbVie
- 8.5.1 AbbVie Company Information
- 8.5.2 AbbVie Business Overview
- 8.5.3 AbbVie Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 AbbVie Chronic Kidney Disease Drugs Product Portfolio
- 8.5.5 AbbVie Recent Developments
- 8.6 Amgen
- 8.6.1 Amgen Company Information
- 8.6.2 Amgen Business Overview
- 8.6.3 Amgen Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Amgen Chronic Kidney Disease Drugs Product Portfolio
- 8.6.5 Amgen Recent Developments
- 8.7 GlaxoSmithKline
- 8.7.1 GlaxoSmithKline Company Information
- 8.7.2 GlaxoSmithKline Business Overview
- 8.7.3 GlaxoSmithKline Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GlaxoSmithKline Chronic Kidney Disease Drugs Product Portfolio
- 8.7.5 GlaxoSmithKline Recent Developments
- 8.8 Pfizer
- 8.8.1 Pfizer Company Information
- 8.8.2 Pfizer Business Overview
- 8.8.3 Pfizer Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pfizer Chronic Kidney Disease Drugs Product Portfolio
- 8.8.5 Pfizer Recent Developments
- 8.9 Sanofi
- 8.9.1 Sanofi Company Information
- 8.9.2 Sanofi Business Overview
- 8.9.3 Sanofi Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Sanofi Chronic Kidney Disease Drugs Product Portfolio
- 8.9.5 Sanofi Recent Developments
- 8.10 Teva Pharmaceutical Industries
- 8.10.1 Teva Pharmaceutical Industries Company Information
- 8.10.2 Teva Pharmaceutical Industries Business Overview
- 8.10.3 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Product Portfolio
- 8.10.5 Teva Pharmaceutical Industries Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Chronic Kidney Disease Drugs Value Chain Analysis
- 9.1.1 Chronic Kidney Disease Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Chronic Kidney Disease Drugs Production Mode & Process
- 9.2 Chronic Kidney Disease Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Chronic Kidney Disease Drugs Distributors
- 9.2.3 Chronic Kidney Disease Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst